To date, no compounds or interventions exist that treat or prevent sarcomeric
cardiomyopathies. Established therapies currently improve the outcome, but novel therapies …

Hypertrophic (HCM) and dilated (DCM) cardiomyopathies are inherited diseases with a high
incidence of death due to electric abnormalities or outflow tract obstruction. In many of the …

Human atrial and ventricular contractions have distinct mechanical characteristics including
speed of contraction, volume of blood delivered and the range of pressure generated …

Hypertrophic cardiomyopathies (HCM) result from distinct single-point mutations in
sarcomeric proteins that lead to muscle hypercontractility. While different models account for …

Myosin motors are the fundamental force-generating elements of muscle contraction.
Variation in the human β-cardiac myosin heavy chain gene (MYH7) can lead to hypertrophic …

The heart adjusts its power output to meet specific physiological needs through the
coordination of several mechanisms, including force-induced changes in contractility of the …

Hypertrophic cardiomyopathy (HCM) affects 1 in 500 individuals and is an important cause
of arrhythmias and heart failure. Clinically, HCM is characterized as causing …

The genetic advantages of Drosophila make it a very appealing choice for investigating
muscle development, muscle physiology and muscle protein structure and function. To take …

Nearly all mechanochemical models of the cross-bridge treat myosin as a simple linear
spring arranged parallel to the contractile filaments. These single-spring models cannot …

Muscle contraction results from cyclic interactions between the contractile proteins myosin
and actin, driven by the turnover of adenosine triphosphate (ATP). Despite intense studies …